Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against hard targets and undruggable proteins
Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation
The Selectivity of Translation Biology
Cells control protein translation using multiple selective mechanisms, offering novel intervention points. Modulation of translation is therefore possible with highly selective drugs.
mRNA translation modulators
A novel target space
Selective translation modulators with novel mechanisms of action elucidated by Anima’s proprietary technologies
Translation Control Therapeutics platform
Our proprietary platform controls mRNA Translation Biology
Anima’s science is using fluorescently labeled tRNA pairs to generate FRET signals, light pulses emitted from the ribosomes to visualize the translation of any protein of interest and identify selective translation modulators
mRNA Translation Modulators Pipeline
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), Oncology (c-Myc translation inhibitors and K-Ras translation inhibitors), Neuroscience (mHTT translation inhibitors, expanded to a broader strategy against Repeat Associated Diseases) and Infectious diseases (RSV viral proteins translation inhibitors)
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact [email protected].
17 Scientific Collaborations
Nucleic Acids Res. 2020 ;46(6):e32
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
News & Events
3rd Annual RNA-Targeted Drug Discovery Conference
When: Dec. 8th, 2020 - Dec. 10th, 2020
Anima Biotech has been invited to present and participate in multiple sessions during the 3rd Annual RNA-Targeted Drug Discovery Conference, between Dec. 8-10, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” and will also serve on an expert panel, titled, “From Theory to Reality: How to Target RNA Biology with Small Molecule Approaches.” Iris Alroy, VP of R&D, will also participate in an expert Q&A session.
2nd Annual RNA as a Drug Target Conference
When: Sep. 16th, 2020 - Sep. 18th, 2020
Anima Biotech has been invited to present and participate on an expert panel during the Cambridge Healthtech Institute’s 2nd Annual RNA as a Drug Target Conference, between Sep. 16-17, 2020. Yochi Slonim, Co-founder and CEO of Anima Biotech, will be giving a presentation during the RNA as a Drug Target session, titled, “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators, on Thursday, Sep. 17 at 10:15 a.m. ET. As part of the same session, Dr. Iris Alroy, VP of R&D, will participate on an expert wrap-up panel discussion on Thursday, Sep. 17 at 11:35 a.m. ET.
Cambridge Healthtech Institute’s Inaugural RNA as a Small Molecule Target Symposium
When: Aug. 28th, 2020
Anima Biotech has been invited to give an overview of its Translation Control Therapeutics platform at the Inaugural RNA as a Small Molecule Target Symposium. Co-founder and CEO, Yochi Slonim and vice president of research and development Dr. Iris Alroy will jointly present a talk titled “Translation Control Therapeutics: Discovery of Selective mRNA Translation Modulators,” on Friday, Aug.